MBP and myeloid sarcoma: Exposure of PBMCs from MS patients to MBP peptides resulted in significantly enhanced proportions of HLA-DR+ cells, estimated as 13.6, 23.8, and 41.1% on incubation with GH17, GK16, and QR24, respectively.